Aravindhan Veerapandiyan, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Biogen, Novartis, AveXis, Sarepta therapeutics, PTC therapeutics, Scholar Rock, Fibrogen, AMO pharma, Pfizer, Edgewise therapeutics
    Topic: 
    Ad Hoc Advisory boards
    Date added: 
    12/22/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Sarepta, Fibrogen, Pfizer, Octapharma, Regenxbio, Edgewise therapeutics, Amgen, Lilly, Teva therapeutics, Impax, Capricor therapeutics, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, and France Foundation
    Topic: 
    Research / Grant Support
    Date added: 
    12/22/2022
Return to 45th Annual Carrell Krusen Neuromuscular Symposium (RP2302A)